Overall Vote Recommendation

Principle Criteria

Free Enterprise

Property Rights

Personal Responsibility

Limited Government

Individual Liberty

In Layman's Terms

SB 5 creates the Dementia Prevention and Research Institute of Texas to fund research on dementia, Alzheimer's, Parkinson's, and related diseases through competitive grants. The bill establishes the institute's governance, oversight, and grant process, contingent on voter approval of a constitutional amendment creating its dedicated funding source.

Digest

SB 5 establishes the Dementia Prevention and Research Institute of Texas, a state agency responsible for coordinating and funding research on dementia, Alzheimer’s disease, Parkinson’s disease, and related disorders. The bill outlines a detailed governance structure that includes a nine-member Oversight Committee appointed by the Governor, Lieutenant Governor, and Speaker of the House, as well as a Peer Review Committee and a Program Integration Committee responsible for evaluating and recommending grant proposals.

The Institute is tasked with awarding competitive grants to institutions of higher education, research facilities, public and private entities, and collaboratives. Grant funding supports scientific research, translational and clinical studies, facilities and equipment, and strategies for prevention. The bill gives priority to proposals with matching private or nonprofit funds, interdisciplinary approaches, or demonstrable economic and scientific benefits to the state.

SB 5 establishes the Dementia Prevention and Research Fund, a constitutionally dedicated fund administered by the Institute and financed with a proposed $3 billion transfer from general revenue (contingent on voter approval of a constitutional amendment). The fund may be used for grants, operational costs, and facility purchases.

The bill includes robust conflict-of-interest policies, grant oversight and compliance mechanisms, and financial auditing procedures, including mandatory reporting by the Institute to the Legislature, Comptroller, and public. A matching funds requirement applies to all non-public recipients, and the state retains a financial interest in capital improvements and intellectual property developed with grant funds. The House Committee Substitute expanded the scope of the institute to explicitly include Alzheimer’s and Parkinson’s diseases, strengthened compliance provisions, and clarified matching fund rules and allowable grant uses.

Author (1)

Joan Huffman

Co-Author (13)

Carol Alvarado Brian Birdwell Cesar Blanco Donna Campbell Brent Hagenbuch Juan Hinojosa Nathan Johnson Jose Menendez Borris Miles Tan Parker Angela Paxton Royce West Judith Zaffirini

Sponsor (5)

Tom Craddick Senfronia Thompson Todd Hunter Greg Bonnen Pat Curry

Co-Sponsor (120)

Alma Allen Rafael Anchia Trent Ashby Jeffrey Barry Cecil Bell, Jr. Keith Bell Salman Bhojani Rhetta Bowers John Bryant Bradley Buckley John Bucy III Ben Bumgarner Angie Chen Button Elizabeth Campos Terry Canales Giovanni Capriglione Sheryl Cole Nicole Collier David Cook Philip Cortez Charles Cunningham Drew Darby Aicha Davis Yvonne Davis Jay Dean Mano DeAyala Mark Dorazio Harold Dutton Paul Dyson Caroline Fairly Lulu Flores James Frank Erin Gamez Cassandra Garcia Hernandez Josey Garcia Linda Garcia Gary Gates Stan Gerdes Charlie Geren Barbara Gervin-Hawkins Jessica Gonzalez Mary Gonzalez Vikki Goodwin Robert Guerra Ryan Guillen Sam Harless Cody Harris Caroline Harris Davila Richard Hayes Cole Hefner Ana Hernandez Gina Hinojosa Donna Howard Lacey Hull Ann Johnson Jolanda Jones Venton Jones Helen Kerwin Ken King Stan Kitzman Marc LaHood Suleman Lalani Stan Lambert Brooks Landgraf Jeff Leach Terri Leo-Wilson Mitch Little Oscar Longoria Janie Lopez Ray Lopez A.J. Louderback J. M. Lozano John Lujan Christian Manuel Armando Martinez Trey Martinez Fischer Don McLaughlin John McQueeney William Metcalf Morgan Meyer Terry Meza Joseph Moody Penny Morales Shaw Christina Morales Eddie Morales Matt Morgan Sergio Munoz, Jr. Candy Noble Tom Oliverson Claudia Ordaz Angelia Orr Jared Patterson Dennis Paul Mary Perez Vincent Perez Dade Phelan Mihaela Plesa Richard Raymond Ron Reynolds Ana-Maria Ramos Ramon Romero, Jr. Toni Rose Jon Rosenthal Michael Schofield Alan Schoolcraft Matthew Shaheen Joanne Shofner Lauren Simmons John Smithee David Spiller James Talarico Steve Toth Chris Turner Gary Vandeaver Denise Villalobos Armando Walle Charlene Ward Johnson Terry Wilson Eugene Wu Erin Zwiener

Contact the Author

Sen. Joan Huffman

Capitol Phone:

(512) 463-0117

Capitol Office:

EXT E.14

E-Mail:

[email protected]

Visit Official Website

Fiscal Notes

According to the Legislative Budget Board (LBB), SB 5 has no net impact on General Revenue–Related Funds during the 2026–27 biennium, with the estimated impact remaining $0 through fiscal year 2030. This is because the bill itself does not appropriate money. Instead, it establishes the legal framework for the Dementia Prevention and Research Institute of Texas (DPRIT) and authorizes future appropriations if voters approve the accompanying constitutional amendment. The fiscal effects associated with the initial capitalization of the institute are reflected separately in the fiscal note for the companion constitutional amendment, SJR 3.

If the constitutional amendment is approved, the Dementia Prevention and Research Fund would receive an initial $3.0 billion transfer from the General Revenue Fund, although that transfer is not scored against this bill. The legislation would authorize DPRIT to award up to $300 million annually in research grants and related expenditures from the new fund. The fund could also receive future legislative appropriations, gifts, grants, and other revenue sources, while any interest, dividend, patent, royalty, or licensing income generated by the fund would be deposited into the General Revenue Fund.

The LBB estimates that operating the institute would require approximately 54 full-time employees and $22.4 million in annual administrative expenses, including personnel, rent, professional services, travel, and other operating costs. These administrative expenses would be paid from the Dementia Prevention and Research Fund rather than from General Revenue. The remaining annual expenditures, bringing total authorized spending to approximately $300 million per year, would primarily support competitive research grants and related institute activities. Because future patent, royalty, and licensing income cannot be predicted, the LBB identifies those potential revenues as indeterminate.

The LBB also concludes that no fiscal impact to local governments is anticipated. The bill would take effect only upon voter approval of the companion constitutional amendment, with an effective date of December 1, 2025.

Vote Recommendation Notes

SB 5, while rooted in a well-meaning desire to expand research and innovation around dementia and related neurological disorders, represents a significant and ongoing expansion of state government into a domain that has historically been, and continues to be, well served by private-sector innovation and nonprofit research institutions. As revised by the House Public Health Committee, the bill not only establishes the Dementia Prevention and Research Institute of Texas (DPRIT) as a permanent state agency but also broadens its mandate to explicitly include Alzheimer’s disease, Parkinson’s disease, and related disorders. While the scope of covered diseases is now wider, the core concerns remain the same: this bill creates a permanent, publicly funded entity that duplicates many functions already being carried out by universities, research hospitals, and pharmaceutical firms.

The updated House version maintains the original structure of a new government bureaucracy, comprising an Oversight Committee, a Peer Review Committee, a Program Integration Committee, and multiple advisory bodies, including a Higher Education Advisory Committee populated exclusively by appointees from Texas university systems. The inclusion of these bodies reinforces the concern that DPRIT is being designed to favor large, entrenched institutions over smaller, private, or independent research efforts. Furthermore, the matching grant requirements and annual $300 million in allocations set up a pipeline of public money that may be inaccessible to newer or nontraditional entrants in the research space, further cementing institutional favoritism.

Moreover, the bill outlines an administrative apparatus with a projected annual cost of $22.4 million, including 54 new full-time state employees, to manage the program's operations. These are recurring costs paid out of a newly created fund that will be capitalized by a $3 billion transfer from General Revenue, contingent upon voter approval of a related constitutional amendment. Even though SB 5 does not appropriate funds directly, it clearly lays the statutory framework for that appropriation. The sheer scale of the fund, and its constitutional dedication, amounts to a long-term fiscal commitment that bypasses the normal annual budgetary scrutiny and ties up taxpayer dollars for a single policy domain at the expense of others.

Supporters of SB 5 may argue that government investment can supplement private research, but this bill does more than support; it establishes a permanent, government-run research institute with broad authority, independent hiring power, and perpetual funding. This approach contrasts with the core liberty principle of limited government, which calls for restraint in the creation and maintenance of taxpayer-funded agencies. Rather than spurring free-market solutions, SB 5 risks crowding them out by creating an entity that can pick winners and losers in the field of medical research based on bureaucratic review and political appointments.

Texas Policy Research continues to recommend that lawmakers vote NO on SB 5. While the cause it seeks to address is laudable, the mechanism by which it attempts to do so is not. A $3 billion constitutional carveout and a new government agency are not compatible with the principles of free enterprise, personal responsibility, or limited government. There are better ways to support dementia research, ones that involve incentivizing private innovation, not expanding taxpayer-funded bureaucracy.

Free Enterprise

This is one of the most affected liberty principles. The bill inserts the state as a major player in the biomedical research marketplace through a $3 billion taxpayer-funded initiative. Although the grants are competitive, the structure favors established academic and institutional players, as evidenced by the composition of the advisory committees and matching fund requirements. Smaller startups, private labs, and nonprofit innovators may be effectively excluded or disadvantaged due to bureaucratic hurdles, limiting open competition and innovation in a field best served by market dynamism.

Property Rights

The bill includes provisions that allow the state to retain intellectual property rights, collect royalties, and place liens on capital improvements developed with state grant funds. While this is designed to recoup taxpayer investment, it also means that any private or nonprofit entity accepting grant money may sacrifice full control over the outputs of their work. This creates a contractual limitation on private property rights for participants in the program, even if it is voluntarily accepted.

Personal Responsibility

The bill neither encourages nor discourages personal responsibility in a direct manner. It is focused on research and infrastructure investment, not on individual behavioral interventions. However, by prioritizing state-funded solutions to complex health problems, it may reinforce a public expectation that the government, not individuals or families, should be the primary driver of long-term healthcare solutions.

Limited Government

The bill marks a substantial expansion of government power and permanence. It creates a new state agency with a large administrative staff, perpetual funding, rulemaking authority, and oversight structures. It also commits the state to a constitutionally dedicated fund, shielding it from future legislative scrutiny or prioritization. This is a textbook example of permanent bureaucratic expansion into a domain already populated by capable private actors, and thus conflicts directly with the principle of limited government.

Individual Liberty

The bill does not impose mandates on individuals, nor does it restrict personal freedoms. However, the creation of a centralized, state-run research institution with constitutionally dedicated funds could indirectly reduce individual choice over time by crowding out private research efforts or influencing funding priorities through political processes rather than decentralized market demand. This government-led direction in medical research may subtly erode the individual’s influence over healthcare innovation priorities.

Committee Vote Information

Senate Committee on Finance: 14Y/0N (1 Absent)
House Committee on Public Health : 9Y/2N (2 Absent)

References

Texas Dementia Prevention and Research Institute: A Costly Overreach in the Wrong Direction

Related Legislation

View Bill Text and Status